PREPARATION AND EVALUATION OF THE ANTIVIRAL ACTIVITY OF ACYCLOVIR LOADED NANO-NIOSOMES AGAINST HERPES SIMPLEX VIRUS TYPE 1

被引:0
|
作者
Javad, Mirzaei Parsa Mohamad [1 ]
Reza, Monavari S. Hamid [2 ]
Simin, Dadashzadeh [3 ]
Ahmed, Ebrahimi S. [4 ]
Bahram, Bolouri [5 ]
Azadeh, Haeri [3 ]
机构
[1] Univ Tehran Med Sci, Sch Adv Med Technol, Tehran, Iran
[2] Iran Univ Med Sci, Sch Med, Dept Virol, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Sch Pharm, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Med, Dept Pharmacol, Tehran, Iran
[5] Univ Tehran Med Sci, Dept Med Phys & Engn, Tehran, Iran
来源
PHARMACOPHORE | 2014年 / 5卷 / 04期
关键词
Acyclovir; Nano-niosomes; Herpes simplex virus;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acyclovir (ACV), analog of 2'-deoxyguanosine, is known for its antiviral activity against Herpes simplex virus (HSV). A major limitation of treatment with acyclovir is high distribution and low half-life that leads to taking high doses of acyclovir. Recent studies have shown that entrapment of acyclovir in nano-carriers can increase effectiveness and also decrease side effects of the drug. Therefore, in the present study the preparation and characterization of acyclovir loaded nanoniosomes was investigated. The non-ionic surfactant vesicles were prepared by thin film hydration method. The lipid composition in optimal formulation consisted of Span, cholesterol and D-. tocopheryl polyethylene glycol succinate (TPGS) in the molar ratio of 55 : 30 : 15, respectively. Physical characteristics of optimized niosomes such as particle size, encapsulation efficiency (EE) and in vitro drug release were evaluated. Furthermore, the in vitro cytotoxicity study of empty niosomes (E-N), acyclovir loaded niosomes (ACV-N) and ACV as a free drug against Hela cell line was performed by MTT assay. The average of particle size and EE for optimized niosomes were 122.6 +/- 0.2 nm and 24 % respectively. The drug release profiles proved the efficacy of optimized niosomes in prolonged release of ACV, so that the percent drug release for 1h was recorded as approximately 11.7 %. The prepared niosomes also showed significant stability with regard to particle size and EE when stored at least for seven days at 5 degrees C. The results of this study revealed ACV-N (F5) have a higher antiviral activity compared with free drug, and could be a suitable carrier for delivery of acyclovir in the treatment of HSV-1 infections.
引用
收藏
页码:483 / 493
页数:11
相关论文
共 50 条
  • [1] Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer
    Mohamad Javad Mirzaei-Parsa
    Mohammad Reza H. Najafabadi
    Azadeh Haeri
    Masoumeh Zahmatkeshan
    Soltan Ahmad Ebrahimi
    Hamidreza Pazoki-Toroudi
    Moein Adel
    Breast Cancer, 2020, 27 : 243 - 251
  • [2] Preparation, characterization, and evaluation of the anticancer activity of artemether-loaded nano-niosomes against breast cancer
    Mirzaei-Parsa, Mohamad Javad
    Najafabadi, Mohammad Reza H.
    Haeri, Azadeh
    Zahmatkeshan, Masoumeh
    Ebrahimi, Soltan Ahmad
    Pazoki-Toroudi, Hamidreza
    Adel, Moein
    BREAST CANCER, 2020, 27 (02) : 243 - 251
  • [3] Antiviral Activity of Oridonin Against Herpes Simplex Virus Type 1
    Jiang, Kai
    Feng, Jing
    Qi, Xia
    Ran, Lili
    Xie, Lixin
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 4311 - 4323
  • [4] Antiviral activity of Viracea® against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus
    Thompson, KD
    ANTIVIRAL RESEARCH, 1998, 39 (01) : 55 - 61
  • [5] Antiviral activity of theaflavin digallate against herpes simplex virus type 1
    de Oliveira, Aline
    Prince, Derek
    Lo, Chih-Yu
    Lee, Lee H.
    Chu, Tin-Chun
    ANTIVIRAL RESEARCH, 2015, 118 : 56 - 67
  • [6] Antiviral activity of a selective ribonucleotide reductase inhibitor against acyclovir-resistant herpes simplex virus type 1 in vivo
    Duan, JM
    Liuzzi, M
    Paris, W
    Lambert, M
    Lawetz, C
    Moss, N
    Jaramillo, J
    Gauthier, J
    Déziel, R
    Cordingley, MG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (07) : 1629 - 1635
  • [7] In vitro antiviral activity of dermaseptins against herpes simplex virus type-1
    Belaid, A
    Aouni, M
    Khelifa, R
    Trabelsi, A
    Jemmali, M
    Hani, K
    JOURNAL OF MEDICAL VIROLOGY, 2002, 66 (02) : 229 - 234
  • [8] Antiviral screening of four plant extracts against acyclovir resistant herpes simplex virus type-1
    Parsania, Masoud
    Rezaee, Mohammad-Bagher
    Monavari, Seyed Hamidreza
    Jaimand, Kamkar
    Mousavi-Jazayeri, Seyed Milad
    Razazian, Mehdi
    Nadjarha, Mohammad Hossein
    PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 30 (04) : 1407 - 1411
  • [9] Increased efficacy of acyclovir-loaded microparticles against herpes simplex virus type 1 in cell culture
    de Jalón, EG
    Blanco-Príeto, MJ
    Ygartua, P
    Santoyo, S
    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2003, 56 (02) : 183 - 187
  • [10] Synergistic antiviral activity of acyclovir and vidarabine against herpes simplex virus types 1 and 2 and varicella-zoster virus
    Suzuki, Mikiko
    Okuda, Tomoko
    Shiraki, Kimiyasu
    ANTIVIRAL RESEARCH, 2006, 72 (02) : 157 - 161